KR100948679B1 - A hangover curing composition containings cis???Hexadecenoic acid or 2???2?Aminoethyl?amino?ethanol as an active ingredient - Google Patents

Abstract

The present invention relates to a hangover composition comprising the compound represented by the formula (1) or (2) as an active ingredient, more specifically cis-9-hexadecenoic acid (palmitoleic acid) represented by the formula (1) of the present invention ) [cis-9-Hexadecenoic acid (Palmitoleic acid)] or 2-[(2-aminoethyl) amino] ethanol represented by the formula (2) is the acetaldehyde degrading activity and It can be usefully used for hangover elimination by exhibiting alcohol degrading activity.

<Formula 1>

<Formula 2>

Cis-9-hexadecenoic acid (palmitoreic acid), 2-[(2-aminoethyl) amino] ethanol, hangover elimination, acetaldehyde decomposing activity, alcohol decomposing activity

Description

Hangover curing composition containing cis-９-Hexadecenoic acid or 2-[(2-Aminoethyl) containing cis- hexa- hexadecenoic acid and 2- [(2-aminoethyl) amino] ethanol as an active ingredient Amino] ethanol as an active ingredient}

The present invention relates to a hangover composition comprising the compound represented by the formula (1) or (2) as an active ingredient, more specifically cis-9-hexadecenoic acid (palmitoleic acid) represented by the formula (1) of the present invention ) [cis-9-Hexadecenoic acid (Palmitoleic acid)] or 2-[(2-aminoethyl) amino] ethanol represented by the formula (2) {2-[(2-Aminoethyl) amino] ethanol} as an active ingredient It relates to a hangover composition.

Alcohol paralyzes the restraint of the brain and shows an excited state when ingested. It suppresses consciousness and movement, and has a sleep and anesthetic effect, which is a major favorite food for modern people who are stressed. Korea's drinking culture continues to grow with economic growth, and the current level of alcohol consumption per individual is the highest in the world. However, alcohol can develop into addiction when excessively ingested, and poses a threat to personal health that damages not only the central nervous system such as the brain, but also the metabolic organs such as the digestive system and the liver. In addition, the increase in traffic accidents due to drunk driving, etc. is emerging as a social problem, and the demand for foods or drugs that can minimize the effects of alcohol on the human body is also increasing.

The hangover phenomenon after drinking alcohol is caused by the toxic action of ethyl alcohol or acetaldehyde accumulated in hepatocytes, and the toxic action lasts for a long time, causing metabolism and the like. Specifically, in normal ethyl alcohol metabolism, when ethyl alcohol enters the body, it is absorbed by the gastrointestinal or small intestine, enters the blood vessels, and moves to the liver, and the liver cells have alcohol dehydrogenase, which oxidizes alcohol to acetaldehyde, and the acetaldehyde Acetic acid dehydrogenase in hepatocytes decomposes acetic acid and transfers it to muscles and adipose tissues throughout the body and finally into carbon dioxide and water.

In addition, the acetaldehyde dehydrogenase has a type II which functions even at low concentrations of acetaldehyde and a type I which functions only at high concentrations of acetaldehyde, but oriental people generally lack or lack an acetaldehyde dehydrogenase of type II. Acetaldehyde is not readily degraded. Therefore, damage of hepatocytes and brain cells is caused by the toxic action of unoxidized acetaldehyde and ethyl alcohol. In addition, various electrolytes are discharged to the outside of the body together with a lack of water and water due to the dehydration of alcohol, and the electrolyte is insufficient. Normal metabolism is disturbed due to the above causes, causing various hangovers such as vomiting, headache, chills and abdominal pain.

In order to solve the hangover phenomenon after drinking, a number of hangover medicinal products are prepared, which are prepared by mixing or using herbal medicines or artificial preparations. This inconvenience is limited to use. Therefore, while solving the above problems, there is a demand for the development of an economic and effective hangover relievers.

Accordingly, the present inventors have identified the activity and functionality of cis-9-hexadecenoic acid (palmitorenoic acid) and 2-[(2-aminoethyl) amino] ethanol compound, and as a result, acetaldehyde decomposing activity and alcohol decomposing activity The present invention has been completed by discovering that it can be usefully used for hangover relief.

An object of the present invention is cis-9-hexadecenoic acid (palmitoleic acid) [cis-9-Hexadecenoic acid (Palmitoleic acid)] or 2-[(2-aminoethyl) amino] ethanol {2-[(2- Aminoethyl) amino] ethanol} It is to provide a hangover composition containing the compound as an active ingredient.

In order to achieve the above object, the present invention provides a hangover releasing agent containing a compound represented by the following formula (1) as an active ingredient.

In addition, the present invention provides a hangover releasing agent containing a compound represented by the following formula (2) as an active ingredient.

In addition, the present invention provides a health functional food for hangover relief containing the compound represented by the following formula (1) as an active ingredient.

In addition, the present invention provides a dietary supplement for hangover containing the compound represented by the following formula (2) as an active ingredient.

Cis-9-hexadecenoic acid (palmitoleic acid) [cis-9-Hexadecenoic acid (Palmitoleic acid)] or 2-[(2-aminoethyl) amino] ethanol {2-[(2-Aminoethyl) amino of the present invention ] ethanol} compound can be useful for hangover elimination by showing acetaldehyde and alcohol degradation activity.

Hereinafter, the present invention will be described in detail.

The present invention provides a hangover resolver containing a compound represented by the following formula (1) or (2) as an active ingredient.

<Formula 1>

<Formula 2>

Compound represented by the formula (1) or formula (2) of the present invention can be used by appropriately selected or extracted by a method well known in the art of the present invention, the method or material is not particularly limited.

In the present invention, Formula 1 and Formula 2 were prepared by the following method.

1) Theragra chalcogramma ) with methanol;

2) adding an organic solvent to the extract of step 1) to prepare an organic solvent fraction;

3) adsorbing the fraction of step 2) by column chromatography and obtaining an active fraction obtained by applying a concentration gradient consisting of toluene: acetone: methanol; And

4) adsorbing the active fraction of step 3) to secondary column chromatography and obtaining an active compound which can be obtained by applying a concentration gradient consisting of water: methanol,

In the above production method, the yellow of step 1) can be used without limitation to those produced or marketed. During the extraction, methanol is preferably added by adding 5 to 15 times the amount of yellow, and more preferably, extracted 10 times. After adding the solvent, reflux cooling is preferably performed. The temperature at the time of extraction is preferably 0 ~ 40 ℃, more preferably 40 ℃ but not limited thereto. In addition, the extraction time is preferably 5 to 15 days, more preferably 10 days is not limited thereto. In addition, the number of times the extraction is preferably 1 to 5 times, more preferably three times repeated extraction is not limited thereto. After extracting and filtering the yellow matter by the above method, the filtrate was concentrated under reduced pressure to obtain a yellow extract.

In the above production method, the organic solvent of step 2) is preferably fractionated into n-hexane, ethyl acetate and butanol, and more preferably ethyl acetate or butanol is used. In the present invention, ethyl acetate or butanol fractions were concentrated under reduced pressure.

In the above method, the column chromatography of steps 3) and 4) is composed of silica gel, Sephadex, LH-20, octadecylsilica (ODS), RP-18, polyamide, Toyopearl and XAD resin. Column chromatography using a filler selected from can be performed to isolate and purify the active compound. Column chromatography can be carried out several times by selecting the appropriate filler as required. In the present invention, the ethyl acetate fraction of sulfur is adsorbed on silica gel column chromatography, and toluene: acetone is first applied to a concentration gradient (100: 0 → 0: 100) as a mobile phase, followed by acetone. : Methanol was applied to the concentration gradient (100: 0 → 0: 100) for the second time, and nine fractions E1 to E9 were sequentially eluted, and acetone: methanol (6: 4) was active fraction (E9). Was obtained (see Table 1). In addition, the butanol fraction of the yellow adsorbed on silica gel column chromatography, and toluene: acetone was first applied to the mobile phase with a concentration gradient (100: 0 → 0: 100), and then acetone: methanol was used. (100: 0 → 0: 100) was applied secondly, and 12 fractions B1 to B12 were eluted sequentially, of which active fraction (B1) was obtained at a concentration of toluene: acetone (10: 0) (Table 2). Reference).

The active fractions (E9 and B1) were respectively adsorbed on octadecylsilica column chromatography in a second step and water (methanol) concentration (70: 30) was applied to the active fraction (E9) to obtain compound 1, activity. Compound 2 was obtained respectively in fraction (B1). The separated compound 1 and compound 2 are cis-9-hexadecenoic acid (palmitoleic acid) represented by Chemical Formula 1 through mass spectrograph (MS) and nuclear magnetic resonance (NMR), respectively. And 2-[(2-aminoethyl) amino] ethanol {2-[(2-Aminoethyl) amino] ethanol} represented by the formula (2).

In the present invention, in order to determine the effect of the compound represented by the formula (1) or formula (2) on the acetaldehyde decomposition activity, after adding the compound represented by the formula (1) or formula (2) to acetaldehyde, respectively, acetaldehyde dehydrogena After the reaction was added (Acetaldehyde dehydrogenase, ALDH) and the change in absorbance was measured. As a result, it was found that the compound represented by the formula (1) or (2) increases the activity of ALDH as compared with the addition of only ALDH as a control. When excess alcohol is ingested in the body, acetaldehyde produced as a breakdown product of alcohol is transmitted to the brain and converted into many harmful compounds, causing symptoms such as increased pulse, sweating, redness, nausea and vomiting, and a hangover. ALDH activity promotes acetaldehyde degradation without causing liver damage. Therefore, it can be seen that the compound represented by Formula 1 or Formula 2 of the present invention can be used as a hangover scavenger by increasing the activity of ALDH to promote acetaldehyde degradation.

In the present invention, in order to determine the effect of the compound represented by the formula (1) or (2) on the alcohol degradation activity, after adding the compounds represented by the formula (1) or (2) to the alcohol, respectively, alcohol dehydrogenase (Alcohol dehydrogenase, After the reaction was added by ADH), the change in absorbance was measured. As a result, it was found that the compound represented by Formula 1 or Formula 2 increases the activity of ADH as compared with the addition of only ADH as a control. Therefore, it can be seen that the compound represented by Formula 1 or Formula 2 of the present invention can be used as a hangover antagonist by increasing the activity of ADH to promote alcohol degradation.

Hangover releasing agent of the present invention may include a pharmaceutically acceptable salt in the compound represented by the formula (1) or formula (2). The pharmaceutically acceptable salts are useful addition salts formed with free acid. Suitable free acids may be organic and inorganic acids, inorganic acids may be hydrochloric acid, bromic acid, sulfuric acid and phosphoric acid, and organic acids may be citric acid, acetic acid, lactic acid, tartariac acid, maleic acid, Fumaric acid, formic acid, propionic acid, oxalic acid, trifluoroacetic acid, benzoic acid, gluconic acid, methanesulfonic acid, glycolic acid, succinic acid, 4-toluenesulfonic acid, galluxuronic acid, embonic acid, glutamic acid or aspartic acid Etc. can be used. Furthermore, not only pharmaceutically acceptable salts, but also all salts, hydrates and solvates that can be prepared by conventional methods may be included.

     Hangover releasing agent of the present invention may optionally contain one or more of the compounds represented by the formula (1) or formula (2), and may further contain one or more active ingredients exhibiting the same or similar functions in addition to the above components.

     Hangover reliever of the present invention can be administered orally or parenterally during clinical administration and can be used in the form of a general pharmaceutical formulation. That is, the hangover releasing agent of the present invention may be administered in various oral and parenteral formulations during actual clinical administration, and when formulated, diluents such as fillers, extenders, binders, wetting agents, disintegrating agents, and surfactants that are commonly used Or using excipients. Solid preparations for oral administration include tablets, pills, powders, granules and capsules, and the like, which may be used in the pharmaceutical composition of the present invention at least one excipient such as starch, calcium carbonate, sucrose, lactose And gelatin etc. are mixed and prepared. In addition to simple excipients, lubricants such as magnesium, styrate and talc are also used. Liquid preparations for oral administration include suspensions, solutions, emulsions and syrups, and may include various excipients such as wetting agents, sweeteners, fragrances and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin. have. Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations and suppositories. As the non-aqueous solvent and the suspension solvent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerol and gelatin may be used. Hangover reliever of the present invention can be via subcutaneous injection, intravenous injection or intramuscular injection during parenteral administration.

Preferred dosages of the hangover resolver of the present invention vary depending on the condition and weight of the patient, the extent of the disease, the form of the drug, the route of administration and the duration, and may be appropriately selected by those skilled in the art.

The present invention also provides a health functional food for hangover resolution containing the compound represented by the formula (1) or (2) as an active ingredient.

The compound represented by the formula (1) or (2) of the present invention may be added as it is or used with other food or food ingredients, and may be appropriately used according to a conventional method. The mixed amount of the active ingredient may be suitably determined depending on the purpose of use (prevention, health or therapeutic treatment). Generally, the compound represented by the formula (1) or (2) of the present invention is added in an amount of 15 parts by weight or less, preferably 10 parts by weight or less based on the raw material in the manufacture of food or beverage. However, in the case of long-term intake for health and hygiene or health control purposes, the amount may be below the above range, and the active ingredient may be used in an amount above the above range because there is no problem in terms of safety.

There is no particular limitation on the kind of food. Examples of the food to which the substance can be added include dairy products including meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, ice cream, various soups, drinks, tea, drinks, Alcoholic beverages and vitamin complexes, and the like and include all of the health foods in the conventional sense.

The health beverage composition of the present invention may contain various flavors or natural carbohydrates, etc. as additional components, as in the general beverage. The above-mentioned natural carbohydrates are glucose, monosaccharides such as fructose, disaccharides such as maltose and sucrose, and polysaccharides such as dextrin and cyclodextrin, sugar alcohols such as xylitol, sorbitol and erythritol. As the sweetening agent, natural sweetening agents such as tautin and stevia extract, synthetic sweetening agents such as saccharin and aspartame, and the like can be used.

In addition to the above, the composition of the present invention includes various nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH regulators, stabilizers, preservatives, glycerin, alcohols, carbonic acid. Carbonating agents and the like used in beverages. In addition, the composition of the present invention may contain a flesh for preparing natural fruit juice, fruit juice beverage and vegetable beverage. These components can be used independently or in combination.

Hereinafter, the present invention will be described in detail by the following Examples, Experimental Examples and Formulation Examples.

However, the following Examples, Experimental Examples, and Formulation Examples specifically illustrate the present invention, and the contents of the present invention are not limited to the following Examples, Experimental Examples, and Formulation Examples.

< Example > Preparation of Compounds Represented by Formula 1 or Formula 2

<1-1> Preparation of Yellow Methanol Extract

Inje Yong-dae Hwang Tae-deok was supported by the Yong-dae Hwang-tae, finely crushed and used as a sample. The experimental group carried out experiments with the Inje Yong-Dae Tae-Hwang produced in Korea. Finely crushed 500 g of yellow, extracted for 10 days in methanol, and then the extract was filtered with a filter paper (185 mmØ, Whatman NO.2, Cat NO. 1002 185), and then rotary evaporator (EYELA NE) -2001 5L, Japan) was concentrated under reduced pressure in a hot bath of 40 ℃ or less. As a result, 56.1 g (11.22%) was obtained.

<1-2> active Fraction  Produce

Suspended methanol extract (54g) of sulfur in 1L of distilled water and placed in a separatory funnel, and then sequentially fractionated solvents in the order of hexane (Hexane), ethyl acetate (EtOAc), butanol (BuOH), and water (H ₂ O). It was. The same procedure was repeated three times, and 10.77 g (19.94%) of hexane fraction, 4.61 g (8.53%) of ethyl acetate fraction, 6.9 g (12.78%) of butanol fraction, and 31.4 g (58.15%) of water-soluble fraction were obtained, respectively.

Silica gel column chromatography was performed using an ethyl acetate fraction layer (9.2 g) in the fraction. Each sample was dissolved in methanol, filled with silica gel, and filled in a glass column (4 × 70 cm, 7734, Merck, Inc.). Each of the nine (E1-E9) subfractions was eluted sequentially to obtain a fraction (E9) having high activity at acetone: methanol concentration (6: 4) (see Table 1).

Conditions of Column Chromatography Fraction Mobile phase toluene Acetone Methanol One 100% 2 90% 10% 3 80% 20% 4 50% 50% 5 20% 80% 6 100% 7 90% 10% 8 80% 20% 9 60% 40%

Sample weight: 4g, Column size: 4cm, Merck silica gel (7734)

In addition, a butanol fraction layer (4 g) was subjected to silica gel column chromatography. Each sample was dissolved in methanol, filled with silica gel, and filled in a glass column (4 × 70 cm, 7734, Merck, Inc.). Each of the 12 small fractions (B1 to B12) was eluted sequentially to obtain a fraction (B1) having high activity at a concentration of toluene: acetone (10: 0) (see Table 2).

Fraction Mobile phase toluene Acetone Methanol One 100% 2 90% 10% 3 80% 20% 4 50% 50% 5 20% 80% 6 100% 7 90% 10% 8 80% 20% 9 60% 40% 10 40% 60% 11 20% 80% 12 100%

Sample weight: 4g, Column size: 4cm, Merck silica gel (7734)

<1-3> Preparation of Active Compound

The active fractions (E9 and B1) were adsorbed on octadecylsilica column chromatography, respectively, and water (methanol) concentrations (70: 30) were applied to the active fraction (E9) to obtain compound 1, the active fraction ( In compound B1, compound 2 was obtained, respectively. The isolated compounds were mass spectrograph (Autospec.M363 series), UV spectrometer (jasco680), infrared spectrometer (IR, FT-3000, Excalibur) and ¹ H- and ¹³ C-nuclear magnetic Cis-9-hexadecenoic acid (palmitolenic acid) represented by the formula (1) and 2-[(2-aminoethyl) amino] ethanol represented by the formula (2) through resonance (nuclear magnetic resonance, Bruker Avance 300) { 2-[(2-Aminoethyl) amino] ethanol}.

< Experimental Example  1> acetaldehyde Dehydrogenase  Active measurement

To 0.1 μl of acetaldehyde, 0.1 μl of the compound represented by Chemical Formula 1 or Chemical Formula 2 was added thereto, and ALDH was added thereto to react for 10 minutes in a water bath at 37 ° C., and then absorbance was measured at 340 nm at a concentration of 1%. The effect on ALDH activity was examined. Negative controls added buffer to ALDH and positive controls added aspartic acid, which is known to increase ALDH activity.

ALDH activity was calculated by the following formula.

ALDH Activity (%) = (B / A) × 100

A: maximum absorbance of the control

B: maximum absorbance of the experiment

As a result, as shown in Table 3, it can be seen that the compound represented by Formula 1 or Formula 2 of the present invention increases the activity of ALDH compared to the control.

ALDH  Effect on activity Experimental group % Increase in maximum absorbance 0.1 μl ALDH + 0.1 μl buffer 100.0 0.1 μl ALDH + 0.1 μl ALDH 458.9 0.1 μl ALDH + 0.1 μl compound 1 192 0.1 μl ALDH + 0.1 μl Compound 2 186 0.1 μl ALDH + 0.1 μl aspartic acid 170

< Experimental Example  2> alcohol Dehydronase  Active measurement

Alcohol dehydrogenase (ADH) activity was expressed by measuring the absorbance of NADH formed at 340 nm using a UV / VIS spectrophotometer (V-530, Jasco) using a modified method of Choi et al. 0.1 μl of alcohol, 0.5 μl of NAD solution (2 μg / μl) and 0.1 μl of the compound were added to each test tube, and 0.01 M glycine-NaOH buffer solution (pH 8.8) was added so that the total volume was 1.8 μl. After 10 minutes of reaction in a constant temperature bath, 0.25 μl of ADH (18 units / μl) was added to measure the change in absorbance at 340 nm. In this case, 0.25 μl of 0.01M glycine-NaOH buffer solution was used instead of ADH. The activity of ADH was expressed as the ratio of the maximum absorbance at the end of the reaction to the maximum absorbance of the control group was calculated as follows.

ADH activity = (B / A) × 100

A: maximum absorbance of the control

B: maximum absorbance of the experiment

As a result, as shown in Table 4, it can be seen that the compound represented by Formula 1 or Formula 2 of the present invention increases the activity of ADH compared to the control.

ADH  Effect on activity Experimental group % Increase in maximum absorbance 0.1 μL of ADH + buffer 100.0 0.1 μL ADH + ADH 452.4 0.1 μl of ADH + compound 1 450 0.1 μl of ADH + Compound 2 727 0.1 μL of ADH + Aspartic Acid 120

Examples of preparations for the compositions of the present invention are illustrated below.

< Formulation example  1> Powder  Produce

20 mg of compound of Formula 1

Lactose 100 mg

Talc 10 mg

The above ingredients are mixed and filled in an airtight cloth to prepare a powder.

Formulation Example 2 Preparation of Tablet

10 mg of compound of Formula 1

Corn starch 100 mg

Lactose 100 mg

2 mg magnesium stearate

After mixing the above components, tablets are prepared by tableting according to a conventional method for preparing tablets.

< Formulation example  3> Preparation of capsule

10 mg of compound of Formula 1

3 mg of crystalline cellulose

Lactose 14.8 mg

Magnesium Stearate 0.2 mg

According to a conventional capsule preparation method, the above ingredients are mixed and filled into gelatin capsules to prepare capsules.

< Formulation example  4> Preparation of Injection

10 mg of compound of Formula 1

Mannitol 180 mg

Sterile distilled water for injection 2974 mg

Na ₂ HPO _{4 ,} 12H ₂ O 26 mg

According to the conventional method for preparing an injection, the amount of the above ingredient is prepared per ampoule (2 ml).

< Formulation example  5> Liquid  Produce

20 mg of compound of formula 2

10 g of isomerized sugar

5 g of mannitol

Purified water

According to the conventional method of preparing a liquid solution, each component is added and dissolved in purified water, lemon flavor is added to the mixture, and then the above ingredients are mixed, purified water is added to adjust the total amount to 100 ml, and then filled in a brown bottle. The solution is prepared by sterilization.

< Formulation example  6> Manufacture of healthy food

1000 mg of compound of formula 2

Vitamin mixture proper amount

70 μg of Vitamin A Acetate

Vitamin E 1.0 mg

Vitamin B1 0.13 mg

Vitamin B2 0.15 mg

Vitamin B6 0.5 mg

0.2 μg of vitamin B12

Vitamin C 10 mg

10 μg biotin

Nicotinic Acid 1.7 mg

50 μg folic acid

Calcium Pantothenate 0.5mg

Mineral mixture

Ferrous Sulfate 1.75 mg

Zinc Oxide 0.82 mg

Magnesium carbonate 25.3 mg

Potassium monophosphate 15 mg

Dibasic calcium phosphate 55 mg

Potassium Citrate 90 mg

Calcium Carbonate 100 mg

Magnesium chloride 24.8 mg

Although the composition ratio of the above-mentioned vitamin and mineral mixtures is mixed with a component suitable for a health food in a preferred embodiment, the compounding ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional health food manufacturing method. The granules may be prepared and used for preparing a health food composition according to a conventional method.

< Formulation example  7> Manufacture of health drinks

1000 mg of compound of formula 2

Citric acid 1000 mg

100 g oligosaccharides

Plum concentrate 2 g

1 g of taurine

900 ml of purified water

After mixing the above components according to a conventional healthy beverage production method, and then stirred and heated at 85 ℃ for about 1 hour, the resulting solution is filtered and obtained in a sterilized 2 L container, sealed sterilization and refrigerated and then stored in the present invention For the preparation of healthy beverage compositions.

Although the composition ratio is a composition that is relatively suitable for the preferred beverage in a preferred embodiment, the compounding ratio may be arbitrarily modified according to regional and ethnic preferences such as demand hierarchy, demand country, and usage.

1 is a schematic diagram showing a process of separating the compound represented by the formula (1) from the Emperor,

Figure 2 is a schematic diagram showing the process of separating the compound represented by Formula 1 and Formula 2 from the Emperor.

Claims (8)

Hangover releasing agent containing a compound represented by the formula (1) as an active ingredient: <Formula 1>

. Hangover releasing agent containing a compound represented by the following formula (2) as an active ingredient: <Formula 2>

. The hangover releasing agent according to claim 1 or 2, wherein the compound represented by Chemical Formula 1 or Chemical Formula 2 exhibits acetaldehyde dehydrogenase activity. The hangover releasing agent according to claim 1 or 2, wherein the compound represented by Chemical Formula 1 or Chemical Formula 2 exhibits alcohol dehydrogenase activity. Hangover functional dietary supplement containing the compound represented by the formula (1) as an active ingredient: <Formula 1>

. Hangover functional health food containing the compound represented by the following formula (2) as an active ingredient: <Formula 2>

. The method of claim 5 or 6, wherein the compound represented by the formula (1) or formula (2) is characterized in that acetaldehyde dehydrogenase (acetaldehyde dehydrogenase) activity, characterized in that hangover relieving health functional food. The method of claim 5 or 6, wherein the compound represented by the formula (1) or formula (2) is characterized by alcohol dehydrogenase activity, hangover relieving health functional food.

Images